Company Analysis Mesoblast Limited
1. Summary
Advantages
- The stock's return over the last year (451.8%) is higher than the sector average (-44.93%).
Disadvantages
- Price (9.93 $) is higher than fair price (5.59 $)
- Dividends (0%) are below the sector average (0.5468%).
- Current debt level 17.77% has increased over 5 years from 8.58%.
- The company's current efficiency (ROE=-17.91%) is lower than the sector average (ROE=9.61%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Mesoblast Limited | Healthcare | Index | |
|---|---|---|---|
| 7 days | 18.1% | -17.5% | -2.3% |
| 90 days | 91.1% | -43.2% | 8.1% |
| 1 year | 451.8% | -44.9% | 31.5% |
MESO vs Sector: Mesoblast Limited has outperformed the "Healthcare" sector by 496.74% over the past year.
MESO vs Market: Mesoblast Limited has outperformed the market by 420.34% over the past year.
Slightly volatile price: MESO is more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical deviations of about +/- 5-15% per week.
Long period: MESO with weekly volatility of 8.69% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (9.93 $) is higher than the fair price (5.59 $).
Price is higher than fair: The current price (9.93 $) is 43.7% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (0.11) is lower than that of the sector as a whole (48.77).
P/E vs Market: The company's P/E (0.11) is lower than that of the market as a whole (48.89).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (1.39) is lower than that of the sector as a whole (4.82).
P/BV vs Market: The company's P/BV (1.39) is lower than that of the market as a whole (3.36).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (113.35) is higher than that of the sector as a whole (33.76).
P/S vs Market: The company's P/S indicator (113.35) is higher than that of the market as a whole (10.23).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-11.54) is higher than that of the sector as a whole (-22.15).
EV/Ebitda vs Market: The company's EV/Ebitda (-11.54) is lower than that of the market as a whole (28.27).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -0.4542% over the last 5 years.
Accelerating profitability: The return for the last year (7.41%) exceeds the average return for 5 years (-0.4542%).
Profitability vs Sector: The return for the last year (7.41%) exceeds the return for the sector (-9.16%).
5.4. ROE
ROE vs Sector: The company's ROE (-17.91%) is lower than that of the sector as a whole (9.61%).
ROE vs Market: The company's ROE (-17.91%) is lower than that of the market as a whole (10.79%).
5.5. ROA
ROA vs Sector: The company's ROA (-13.14%) is lower than that of the sector as a whole (0.3443%).
ROA vs Market: The company's ROA (-13.14%) is lower than that of the market as a whole (6.51%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (-12.89%) is lower than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (-12.89%) is lower than that of the market as a whole (10.79%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5468%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
